Does EPCORITAMAB-BYSP Cause Interstitial lung disease? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Interstitial lung disease have been filed in association with EPCORITAMAB-BYSP. This represents 0.6% of all adverse event reports for EPCORITAMAB-BYSP.
6
Reports of Interstitial lung disease with EPCORITAMAB-BYSP
0.6%
of all EPCORITAMAB-BYSP reports
2
Deaths
1
Hospitalizations
How Dangerous Is Interstitial lung disease From EPCORITAMAB-BYSP?
Of the 6 reports, 2 (33.3%) resulted in death, 1 (16.7%) required hospitalization.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EPCORITAMAB-BYSP. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does EPCORITAMAB-BYSP Cause?
Cytokine release syndrome (369)
Diffuse large b-cell lymphoma (206)
Diffuse large b-cell lymphoma refractory (198)
Pyrexia (79)
Immune effector cell-associated neurotoxicity syndrome (77)
Covid-19 (39)
Neutrophil count decreased (35)
Hypogammaglobulinaemia (32)
Platelet count decreased (32)
Cytomegalovirus infection (31)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which EPCORITAMAB-BYSP Alternatives Have Lower Interstitial lung disease Risk?
EPCORITAMAB-BYSP vs EPERISONE
EPCORITAMAB-BYSP vs EPHEDRINE
EPCORITAMAB-BYSP vs EPINASTINE
EPCORITAMAB-BYSP vs EPINEPHRINE
EPCORITAMAB-BYSP vs EPINEPHRINE\LIDOCAINE